Another study using PD-1 inhibitors revealed that patients with multiple myeloma often exhibited more diarrhea, skin issues, endocrine (hypothyroidism), and musculoskeletal (joint pain) issues, but fewer pulmonary issues (pneumonia and dyspnea) than patients with NSCLC and renal cell carcinoma [41]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.